Pilot Study of Anakinra to Mitigate CAR-T Toxicity in Subjects With Relapsed or Refractory Large B-Cell Lymphoma
Latest Information Update: 30 Jan 2025
At a glance
- Drugs Anakinra (Primary) ; Axicabtagene ciloleucel; Cyclophosphamide; Fludarabine
- Indications B-cell lymphoma; Diffuse large B cell lymphoma; Follicular lymphoma
- Focus Adverse reactions
Most Recent Events
- 29 May 2024 Status changed from active, no longer recruiting to completed.
- 13 Dec 2022 Results assessing safety and efficacy of Anakinra to Mitigate CAR-T Toxicity in Subjects With Relapsed or Refractory Large B-Cell Lymphoma presented at the 64th American Society of Hematology Annual Meeting and Exposition
- 22 Aug 2022 Status changed from recruiting to active, no longer recruiting.